Clinical stage I seminoma: the case for surveillance.
We believe that active surveillance is the optimal choice for compliant men who are able to handle the mental burden of not receiving adjuvant treatment. This takes into consideration the fact that a small number of men with clinical stage I (CSI) seminoma on surveillance will recur but are salvageable with equivalent outcome compared to those having adjuvant treatment which exposes eight in ten men to unnecessary short- and long-term risks with still the possibility of recurrence requiring salvation. This review will focus on CSI seminoma and the controversies surrounding its treatment and based upon current available evidence will outline the case for surveillance.
Lawrentschuk
Nathan
N
Division of Urology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada, nathan.lawrentschuk@uhn.on.ca
Fleshner
Neil
N
D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011159:Population Surveillance / Q000379:methods*; D011859:Radiography; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012307:Risk Factors; D018239:Seminoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy